bpc 157 oral dosing knee pain BPC-157 (Common Protocols), πΉ / Subcutaneous, β’ 500 mcg daily, β’ Duration: 6 weeks, πΉ Intramuscular / Peritendinous, β’ 1 mg daily, β’ Duration: 6 weeks, β οΈ Note:, Not approved by FDA or Peptide Therapy for Inflammation: A
Description
If you have another, use that one instead

For chronic inflammation or autoimmune-related concerns, KPV and VIP deliver targeted anti-inflammatory support under physician supervision

produc Shandong Hanjiang Chemical Co., Ltd

It means be careful and use a clinician, especially if you have IBD or take immune meds
